Head-to-head · free

DexCom, Inc. vs Faeth Therapeutics, Inc.

DXCM vs FTH — return on capital, cash generation, margins and balance sheet side by side.

DXCM

4 / 4

measures where DXCM leads

FTH

0 / 4

measures where FTH leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureDXCM · FY2025FTH · FY2025
Revenue$4.7B—
Net income$836.3M(21.1M)
Revenue growth (yearly, multi-year)17.5%—
Free cash flow$1.1B(20.5M)
Free cash flow margin23.1%—
Net cash / (debt)——
ROIC15.8%—
Return on equity34.5%-74.0%
Gross margin60.1%—
Operating margin19.6%—
Net debt / EBITDA0.28x0.39x

Figures are as reported by each company; latest fiscal year shown.

Where DexCom, Inc.'s cash went (FY2025)

Capital spending
$363.5M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full DXCM profile →

Where Faeth Therapeutics, Inc.'s cash went (FY2025)

Capital spending
$16000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full FTH profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons